Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stevanato Group SpA's total equity for the quarter that ended in Jun. 2026 was €1,550 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
The historical data trend for Stevanato Group SpA's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stevanato Group SpA (FRA:87N) has a Total Equity of €1,550 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Stevanato Group SpA and its competitors.
Is Stevanato Group SpA's Total Equity too high?
Stevanato Group SpA's current Total Equity is €1,550 Mil. Overall, Stevanato Group SpA has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's Total Equity compare to MMED and TFX?
Stevanato Group SpA's Total Equity of €1,550 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Stevanato Group SpA and its competitors. Stevanato Group SpA's current Total Equity is €1,550 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Stevanato Group SpA (FRA:87N) is currently considered Modestly Undervalued. The stock's GF Value™ is €22.30, compared to a current price of €17.40 — trading 22% below its estimated fair value. The current Total Equity is €1,550 Mil. Stevanato Group SpA's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Stevanato Group SpA (FRA:87N), the current Total Equity is €1,550 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (FRA:87N) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of €17.40 is trading 22% below its estimated GF Value™ of €22.30.
GuruFocus considers Stevanato Group SpA to be Modestly Undervalued.
Key valuation signals for FRA:87N:
Total Equity: €1,550 Mil
GF Value™: €22.30 vs. price of €17.40 (22% below fair value)
No single metric tells the full story. See the FRA:87N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
87GF Score
Get the complete analysis for FRA:87N
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:87N has been successfully added to your 
